Dr. Ira Pastan of National Cancer Institute to Speak at Mesothelioma Symposium

Dr. Ira PastanThe Mesothelioma Applied Research Foundation announced that Dr. Ira Pastan, the Head of the National Cancer Institute’s Molecular Biology Section, will be the keynote speaker during its 11th annual International Symposium on Malignant Mesothelioma, taking place on March 5-7 in the Washington, DC metro area.

Alexandria, VA (PRWEB) February 28, 2014

The Mesothelioma Applied Research Foundation announced that Dr. Ira Pastan, the Head of the National Cancer Institute’s Molecular Biology Section, will be the keynote speaker during its 11th annual International Symposium on Malignant Mesothelioma, taking place on March 5-7 in the Washington, DC metro area.

Dr. Pastan is a world-renowned scientist known for his work in cancer research. Along with colleague Mark Willingham, he discovered mesothelin, a protein that is over-expressed in mesothelioma, as well as certain other cancers. This discovery has made it possible to develop an immunotoxin, SS1P, which targets the mesothelin antigen. SS1P has shown much promise in clinical trials by producing major tumor regressions lasting up to two years.

“It is an honor to have Dr. Pastan, one of those most imminent cancer researchers in this nation, joining us at our International Symposium on Malignant Mesothelioma,” said Mary Hesdorffer, NP, the executive director of the Mesothelioma Applied Research Foundation.

“Hearing about his promising work directly from Dr. Pastan will be a very inspiring experience for the mesothelioma patients in attendance, as well as others interested in curing mesothelioma,” she added.

Dr. Pastan will speak to the Symposium audience on Thursday, March 6 at 9:15 AM. The program will also be broadcast live on the web at http://www.curemeso.org/symposium.

Mesothelioma is a malignant tumor of the lining of the lung, abdomen, or heart known to be caused by exposure to asbestos. Medical experts consider it one of the most aggressive and deadly of all cancers. Approximately 3,500 Americans are diagnosed with mesothelioma every year and an estimated one-third were exposed while serving in the Navy or working in shipyards.

ABOUT THE MESOTHELIOMA APPLIED RESEARCH FOUNDATION
The Meso Foundation is the only 501(c)3 non-profit organization dedicated to eradicating mesothelioma and easing the suffering caused by this cancer. The Meso Foundation actively seeks philanthropic support to fund peer-reviewed mesothelioma research; provide patient support services and education; and advocate Congress for increased federal funding for mesothelioma research. The Meso Foundation is the only non-government funder of peer reviewed scientific research to establish effective treatments for mesothelioma and, ultimately, a cure for this extremely aggressive cancer. To date, the Foundation has awarded over $8.7 million to research. More information is available at http://www.curemeso.org.

Rep. Betty McCollum and Rep. Chellie Pingree to Receive Bruce Vento Hope-Builder Award

Congressional Briefing on Malignant MesotheliomaThe Mesothelioma Applied Research Foundation (Meso Foundation) announced that Congresswomen Betty McCollum and Chellie Pingree are the recipients of the Bruce Vento Hope-Builder Award, for sending a letter to Dr. Harold Varmus, Director of the National Cancer Institute, to urge the National Cancer Institute to further mesothelioma research.

Alexandria, VA (PRWEB) February 28, 2014

The Mesothelioma Applied Research Foundation (Meso Foundation) announced that Congresswomen Betty McCollum and Chellie Pingree are the recipients of the Bruce Vento Hope-Builder Award, for sending a letter to Dr. Harold Varmus, Director of the National Cancer Institute, to urge the National Cancer Institute to further mesothelioma research. They will be presented with the award during the International Symposium on Malignant Mesothelioma, on March 6.

Last month, U.S. Congresswomen Betty McCollum (D-MN) and Chellie Pingree (D-ME) sent a “Dear Colleague” letter to all members of the U.S. House of Representatives asking them to join them in urging the National Cancer Institute to create a scientific framework for mesothelioma. The Mesothelioma Applied Research Foundation (Meso Foundation) has long advocated for the National Cancer Institute to increase their focus on mesothelioma, and congratulates Representative McCollum and Representative Pingree for their efforts on behalf of the mesothelioma community, including patients and families, physicians, advocates, and researchers dedicated to eradicating the life-ending and vicious effects of mesothelioma.

The idea for this letter began when Representative Pingree’s constituent, mesothelioma survivor Lisa Gonneville spoke at the Capitol Hill briefing onMesothelioma Awareness Day (September 26).

Mrs. Gonneville, a mother of four and Dayton, ME resident, pleaded that the staffers do something to address this deadly cancer. “I’ve endured all of the treatment options available for mesothelioma, which are very limited,” said Mrs. Gonneville, “my only hope at this point is clinical trials.” Congresswoman Pingree was so moved by Ms. Gonneville’s story that she, too, wanted to help the mesothelioma community in her honor.

“Congresswomen McCollum and Pingree are leading a very important effort for everyone affected by mesothelioma by encouraging the National Cancer Institute to create a scientific framework to progress mesothelioma research,” said Meso Foundation’s executive director and nurse practitioner, Mary Hesdorffer.

“This is an incredible way to help thousands of patients affected by mesothelioma, and also honor our distinguished former board member and Congresswoman McCollum’s predecessor, Bruce Vento.”

Bruce Vento was a prominent member of Congress who, after nearly 24 years of service, succumbed to mesothelioma only eight months after diagnosis.

The Recalcitrant Cancer Research Act of 2012 was signed into law by President Obama on January 2, 2013 as part of the National Defense Authorization Act (Public Law No. 112-239), giving the Director of the National Cancer Institute (NCI) the ability to identify recalcitrant cancers for which to establish scientific frameworks that will guide research efforts.

For each recalcitrant cancer, NCI is to convene a working group of both Federal and non-Federal individuals to provide expertise and assistance in developing the scientific framework. The frameworks are to be completed within 18 months of enactment, then submitted to Congress and made publicly available on the HHS website within 30 days. The bill requires the progress of each scientific framework be reported in the National Institutes of Health (NIH) Biennial Report, with an assessment of progress made in improving outcomes for recalcitrant cancers. The bill further states that the NCI Director “shall consider” each relevant scientific framework when making recommendations for exception funding for grant applications.

Mesothelioma is a malignant tumor of the lining of the lung, abdomen, or heart known to be caused by exposure to asbestos. Medical experts consider it one of the most aggressive and deadly of all cancers. Approximately 3,500 Americans are diagnosed with mesothelioma every year and an estimated one-third were exposed while serving in the Navy or working in shipyards.

ABOUT THE MESOTHELIOMA APPLIED RESEARCH FOUNDATION
The Meso Foundation is the only 501(c)3 non-profit organization dedicated to eradicating mesothelioma and easing the suffering caused by this cancer. The Meso Foundation actively seeks philanthropic support to fund peer-reviewed mesothelioma research; provide patient support services and education; and advocate Congress for increased federal funding for mesothelioma research. The Meso Foundation is the only non-government funder of peer reviewed scientific research to establish effective treatments for mesothelioma and, ultimately, a cure for this extremely aggressive cancer. To date, the Foundation has awarded over $8.7 million to research. More information is available at http://www.curemeso.org.

Mesothelioma Researcher Receives Pioneer Award

Dr. Michele Carbone

Dr. Michele Carbone spoke at the Meso Foundation’s 2013 International Symposium on Malignant Mesothelioma

The Mesothelioma Applied Research Foundation announced today that the 2014 recipient of its Pioneer Award is Michele Carbone, MD, PhD, for his remarkable achievements in mesothelioma research.

Michele Carbone, MD, PhD is a Professor of Pathology and the Director of the University of Hawaii Cancer Center, a National Cancer Institute designated Consortium Cancer Center affiliated with the University of Hawaii – Manoa. He has published over 150 peer-reviewed papers, most in the area of the pathogenesis of mesothelioma.

In addition to his impressive publication record, Dr. Carbone is known in the mesothelioma community for his tireless work in the Turkish region of Cappadocia, where mesothelioma causes 50% of all deaths. Dr. Carbone discovered that a combination of environmental exposures and genetic predisposition were the reason for such a high incidence of mesothelioma among the villagers. Taking his role as a scientist a step further, alongside famed Turkish professor Izzettin Baris, Dr. Carbone demonstrated his compassion by convincing the Turkish government to move and rebuild the affected villages, thus removing them from the environmental exposures.

Dr. Carbone’s studies in Turkey led him to a life-long quest to identify genes implicated in mesothelioma. In 2001, he published in “The Lancet” that predisposition to developing mesothelioma was transmitted as an in an autosomal dominant character in certain Turkish families.

Subsequently, back in the United States, Dr. Carbone and Joseph Testa, PhD led their research team, which included Drs. Giovanni Gaudino, Harvey Pass, Jianming Pei, Mitchell Cheung, and Haining Yang, to study US families with a high incidence of mesothelioma, and through this collaboration discovered the “BAP1 cancer syndrome.” They found this “syndrome” to be caused by germline mutations of the BAP1 gene, which is characterized clinically by a very high risk of developing mesothelioma, melanoma, and other cancers.

Dr. Carbone is known in his field as a generous mentor, and has helped several prolific scientists enter the field of mesothelioma research. Dr. Haining Yang, is one researcher whose work with Dr. Carbone resulted in a peer-reviewed grant award of $100,000 from the Mesothelioma Applied Research Foundation which helped her to develop the data that allowed her two years later to win her NCI-RO1 and DOD grants to study mesothelioma.

“I have worked closely with Dr. Carbone over the years and have been impressed by his kindness and availability,” said Mary Hesdorffer, NP, Meso Foundation’s executive director. “He has been a leader in the field of mesothelioma research, and every one of his many contributions brings us that many steps closer to life-saving treatments for mesothelioma patients.”

The Pioneer Award honors individuals “pioneering” scientific advances in the field of mesothelioma, with the goal of eradicating the life-ending and vicious effects of mesothelioma. The award will be presented during the Awards Dinner, at the International Symposium on Malignant Mesothelioma in Alexandria, VA, on March 5-7.

Mesothelioma is a malignant tumor of the lining of the lung, abdomen, or heart known to be caused by exposure to asbestos. Medical experts consider it one of the most aggressive and deadly of all cancers. Approximately 3,500 Americans are diagnosed with mesothelioma every year and an estimated one-third were exposed while serving in the Navy or working in Navy shipyards.

ABOUT THE MESOTHELIOMA APPLIED RESEARCH FOUNDATION
The Meso Foundation is the only 501(c)3 non-profit organization dedicated to eradicating mesothelioma and easing the suffering caused by it. The Meso Foundation actively seeks philanthropic support to fund peer-reviewed mesothelioma research; provide patient support services and education; and advocate Congress for increased federal funding for mesothelioma research. The Meso Foundation is the only non-government funder of peer reviewed scientific research to establish more effective treatments for mesothelioma and, ultimately, a cure for this extremely aggressive cancer. To date, the Foundation has awarded over $8.7 million to research.

More information is available at http://www.curemeso.org.

UPDATE: Mesothelioma Included in Department of Defense Bill

Congressionally Directed Medical Research Programs logoOn July 24, the U.S. House of Representatives passed a Defense Funding Bill that included $16 million in funding that is eligible to be awarded to mesothelioma research.

The House approved the fiscal year 2014 Defense Appropriations bill (H.R. 2397) on a vote of 315 to 109. The bill includs funding for the Congressionally Directed Medical Research Programs, including the Peer Reviewed Cancer Research Program in which mesothelioma is a topic area.

Each year, the Meso Foundation advocates to continue and increase this vital funding. As a result, $8.8 million dollars has been given to mesothelioma research to date. This is a victory in today’s tough economic climate.

For more information, read our earlier blog regarding this topic.

Cancer Research Awareness Month: Peritoneal Mesothelioma

Screen Shot 2012-06-11 at 3.59.39 PMBy Mary Hesdorffer, Nurse Practitioner and Executive Director of the Meso Foundation

In 1996 I began my career in clinical research which ultimately led to a focus solely on mesothelioma clinical research. At that time, there was no standard of care and clinical trials were being developed that would lead to some significant changes in the way we approach mesothelioma. Peritoneal mesothelioma trials were being written and patients enrolled. Today many of those patients are alive and able to share their experiences from those early efforts. Researchers and patients can now share their collaboration while traveling together through uncharted territories.

During those early years, Hyperthermic intraperitoneal chemotherapy (HIPEC) was being tested at a select number of centers around the country and has now become the standard of care in peritoneal mesothelioma. HIPEC refers to a procedure which starts with a debulking surgery (visible evidence of disease is removed along with a number of involved organs) that is followed by a heated profusion of chemotherapy, delivered directly into the abdomen in an attempt to kill any microscopic disease not removed during the surgical portion of the treatment modality.

The careers of some of the leading doctors in mesothelioma were being established and I am proud to say that most have remained focused on the care of patients with mesothelioma.  In 2004, the first ever international meeting focused on peritoneal mesothelioma took place. I was one of the participants and there was a sense of excitement in the room as we looked around and realized how many brilliant minds were focused on the treatment and understanding of peritoneal mesothelioma. Research has continued with a focus on the type of drugs used during HIPEC as well as ways to augment the response. Doctors are now studying the use of both HIPEC and intravenous therapy to see if they can continue to push the response and survival of those with peritoneal mesothelioma. We know what we do today due to the courage of those early patients and the brilliance of those early pioneers in mesothelioma research.

I refer mainly to these doctors though HIPEC has now been introduced and used for a variety of other cancers. I believe it is important that the researchers have access to tissue,  learn more about the lived experience of mesothelioma through interaction with mesothelioma families, and that new deliveries and new drugs continue to be tested to build upon what we already know. The Mesothelioma Virtual Tissue Bank is a vital resource to our community and our researchers are the ones who maintain and enrich the bank. If patients are directed to non-mesothelioma research centers then this precious source of data and information will be lost.

I have been part of the historical development of mesothelioma and it is my role to see to it that research continues to be funded and patients continue to be supported as they explore their clinical trial options.

If you would like to learn more about mesothelioma research or peritoneal mesothelioma, ask a question through our Ask the Expert feature now.